October 7, 2026
Peering into the research landscape five years ago, you’d often see scientists navigating
expensive or limiting tools to study different layers of biology, with analyses built to explore
one question at a time.
For Cande Rogert, vice president and global head of advanced science, it was another
barrier to overcome, much like the sequencing cost bottleneck she’d helped tackle for 15
years. She and her team are driving a major shift: bringing assays, sequencing, and
analysis together so researchers can explore connected insights across different omes
with ease.
Join us for an inside look at Illumina’s multiomics push: how we’re unifying tools and
disciplines to help researchers uncover deeper insights and make sense of a growing flood
of data. Along the way, meet the leader whose influence extends beyond the bench to the
people and teams around her. Rich Shippy, global head of marketing, sits down with
Cande to explore:
🔶 How bringing sequencing costs down revealed the next bottleneck—and why Illumina
is now pushing to simplify and democratize multiomics
🔶 Cande’s journey to Illumina—how her childhood in Argentina shaped her, and why she
“bleeds Illumina orange”
🔶 Inside the customer conversations shaping Illumina’s multiomics portfolio—
connecting assays, sequencing and analysis to help researchers uncover deeper biological
insights
🔶 A sneak peek at what’s next for Illumina’s multiomics portfolio—and the ambition to
bring more powerful science to labs of every size
Cande’s experiences, from being a new mom and moving across the world twice to helping
drive extraordinary advances in genomics, have shaped her work ethic, optimism and
vision. See the world through her eyes as recounts her journey.
AVAILABLE ON SPOTIFY
Catch up on Episode 1 with Illumina Chief Technology Officer Steve Barnard and Episode 2
with CEO Jacob Thaysen, and Episode 3 with Chief Medical Officer Eric Green.
